Skip to main navigation Skip to search Skip to main content

Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy

  • Huang Zhu
  • , Yi Shin Lai
  • , Ye Li
  • , Robert H. Blum
  • , Dan S. Kaufman

Research output: Contribution to journalReview articlepeer-review

Abstract

Human pluripotent stem cells (PSCs) provide a promising resource to produce immune cells for adoptive cellular immunotherapy to better treat and potentially cure otherwise lethal cancers. Cytotoxic T cells and natural killer (NK) cells can now be routinely produced from human PSCs. These PSC-derived lymphocytes have phenotype and function similar to primary lymphocytes isolated from peripheral blood. PSC-derived T and NK cells have advantages compared with primary immune cells, as they can be precisely engineered to introduce improved anti-tumor activity and produced in essentially unlimited numbers. Stem Cells 2018;36:134–145.

Original languageEnglish (US)
Pages (from-to)134-145
Number of pages12
JournalStem Cells
Volume36
Issue number2
DOIs
StatePublished - Feb 2018
Externally publishedYes

Keywords

  • Adoptive cell therapy
  • Cancer immunotherapy
  • Human pluripotent stem cell
  • Natural Killer cell
  • Natural Killer T cell
  • T cell

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy'. Together they form a unique fingerprint.

Cite this